[Treatment of hypertension syndrome of pregnancy with ligustrazine].

Abstract

75 patients with hypertension syndrome of pregnancy (HSP) were randomly designed to 2 groups: the control group treated with magnesium sulfate (20-25g/d) and the Ligustrazine (120-160mg/d) group. The results of Ligustrazine group compared with the control group were as follows: (1) Mean arterial pressure was significantly decreased (P less than 0.01). (2) Edema and proteinuria was lowered (P less than 0.05). (3) The condition of rheology was improved, especially, hematocrit was significantly decreased (P less than 0.001). (4) The positive rate of NST and Apgar's score were not different between the 2 groups. Clinical monitoring showed Ligustrazine without side effects in the group. Mechanisms of Ligustrazine in HSP were (1) dilating blood vessel; (2) improving kidney function; (3) improving microcirculatory and rheology.

• Authors: X H Qian, Y L Huang, S P Wu
• Journal: Zhong xi yi jie he za zhi = Chinese journal of modern developments in traditional medicine (Zhong Xi Yi Jie He Za Zhi) Vol. 11 Issue 9 Pg. 533-4, 516 (Sep 1991) ISSN: 0254-9034 [Print] China
• PMID: 1773467 (Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Platelet Aggregation Inhibitors
• Pyrazines
• Vasodilator Agents
• Magnesium Sulfate
• tetramethylpyrazine

Topics

• Adult
• Drug Evaluation
• Female
• Humans
• Magnesium Sulfate (therapeutic use)
• Platelet Aggregation Inhibitors (therapeutic use)
• Pre-Eclampsia (drug therapy)
• Pregnancy
• Pyrazines (therapeutic use)
• Vasodilator Agents (therapeutic use)